iBET at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
iBET brings 8 presentations to ESGCT 2026 in Hamburg. Its work centres on engineering and producing viral vectors, from capsid changes that improve AAV transduction to directed evolution of lentiviral vectors. A second strand builds three-dimensional human cell models for testing gene and cell therapies.
| Organization | ESGCT 2026 Attendance |
|---|---|
iBET Oeiras, Portugal | |
Portuguese non-profit research institute working on bioprocesses, viral vector engineering and production, and 3D cell models for biopharmaceuticals. | Workshop Tue Oct 27 11:15am–1:00pm Human 3D Microenvironment Models to Assess Responses to Gene and Cell Therapies Clinical trials and translation Poster Wed Oct 28 1:30pm–3:30pm Enhancing AAV vector transduction efficiency by capsid engineering with nuclear localization signal peptides Poster Wed Oct 28 1:30pm–3:30pm Novel dual-AAV ReCODE system: surpassing the limits of current DNA strategies Poster Wed Oct 28 1:30pm–3:30pm Split-intein circularised Cre: a protease-activated switch for irreversible reporter activation in mammalian cells Poster Thu Oct 29 2:00pm–4:00pm Engineering hiPSC-derived macrophages (eiMACs) to enhance their anti-tumor capacity Poster Thu Oct 29 2:00pm–4:00pm Improving rAAV production for microdystrophin gene therapy through media and feeding optimization Talk Thu Oct 29 4:30pm–6:00pm Unlocking AAV Potential: Precision Capsid Engineering for Scalable Manufacturing Vectors and delivery (AAV, lentiviral, LNP)Manufacturing, CMC and access Talk Thu Oct 29 5:45pm–6:00pm Discovery-driven engineering of lentiviral vectors through directed evolution Vectors and delivery (AAV, lentiviral, LNP) |
Instantly find 20 buyers from iBET
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction